Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study
Authors:
- Ruth LadensteinRLRuth Ladenstein
- Dominique Valteau-CouanetDVDominique Valteau-Couanet
- Penelope BrockPBPenelope Brock
- Isaac YanivIYIsaac Yaniv
- Victoria CastelVCVictoria Castel
- Geneviève LaureysGLGeneviève Laureys
- Josef MalisJMJosef Malis
- Vassilios PapadakisVPVassilios Papadakis
- Ana LacerdaALAna Lacerda
- Ellen RuudEREllen Ruud
- Per KognerPKPer Kogner
- Miklos GaramiMGMiklos Garami
Open Access
- 20 July 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (21) , 3516-3524
Abstract
Purpose To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a rapid delivery schedule) induction. In the High-Risk Neuroblastoma-1 (HR-NBL1) trial, the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim). Patients and Methods From May 2002 to November 2005, 239 patients in 16 countries were randomly assigned to receive or not receive PPGCSF. There were 144 boys with a median age of 3.1 years (range, 1 to 17 years) of whom 217 had International Neuroblastoma Staging System (INSS) stage 4 and 22 had stage 2 or 3 MYCN-amplified disease. The prophylactic arm received a single daily dose of 5 μg/kg GCSF, starting after each of the eight COJEC chemotherapy cycles and stopping 24 hours before the next cycle. Chemotherapy was administered every 10 days regardless of hematologic recovery, provided that infection was controlled. Results The PPGCSF arm had significantly fewer febrile neutropenic episodes (P = .002), days with fever (P = .004), hospital days (P = .017), and antibiotic days (P = .001). Reported Common Toxicity Criteria (CTC) graded toxicity was also significantly reduced: infections per cycle (P = .002), fever (P < .001), severe leucopenia (P < .001), neutropenia (P < .001), mucositis (P = .002), nausea/vomiting (P = .045), and constipation (P = .008). Severe weight loss was reduced significantly by 50% (P = .013). Protocol compliance with the rapid induction schedule was also significantly better in the PPGCSF arm shown by shorter time to completion (P = .005). PPGCSF did not adversely affect response rates or success of peripheral-blood stem-cell harvest. Conclusion Following these results, PPG-GSF was advised for all patients on rapid COJEC induction.Keywords
This publication has 50 references indexed in Scilit:
- Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group StudyJournal of Clinical Oncology, 2005
- Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology GroupJournal of Clinical Oncology, 2005
- Results of Induction Chemotherapy in Children Older Than 1 Year With a Stage 4 Neuroblastoma Treated With the NB 97 French Society of Pediatric Oncology (SFOP) ProtocolJournal of Clinical Oncology, 2005
- Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk NeuroblastomaJournal of Clinical Oncology, 2004
- Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.Journal of Clinical Oncology, 1998
- NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.Journal of Clinical Oncology, 1997
- Biology and Genetics of Human NeuroblastomasJournal of Pediatric Hematology/Oncology, 1997
- Identification of Subsets of Neuroblastomas by Combined Histopathologic and N-myc AnalysisJNCI: Journal of the National Cancer Institute, 1995
- Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in NeuroblastomaEuropean Journal of Cancer, 1995
- Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.Journal of Clinical Oncology, 1991